Watson Bio’s 20-valent pneumococcal polysaccharide conjugate vaccine has been approved for clinical trials
April 22, 2025
Source: drugdu
111
On April 18, Watson Bio (300142) issued an announcement that the 20-valent pneumococcal polysaccharide conjugate vaccine jointly applied for clinical trials by the company and its subsidiaries has obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, with the notice number: 2025LP01099.
The clinical trial of this vaccine will target children aged 2 months (minimum 6 weeks old) to 5 years old to prevent infectious diseases caused by the 20 pneumococcal serotypes contained in this product. This vaccine is an iterative upgrade based on the company's already marketed 13-valent pneumococcal polysaccharide conjugate vaccine, with 7 new serotypes added.
At present, only Pfizer in the United States has launched a 20-valent pneumococcal polysaccharide conjugate vaccine in the world, and there are no related products in China.
In 2024, Watson Bio achieved revenue of 2.821 billion yuan and net profit attributable to shareholders of the parent company of 142 million yuan.
https://finance.eastmoney.com/a/202504183381451832.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Changshan Pharmaceutical’s Nadroparin Calcium Injection Obtains Belarus Drug Registration Certificate May 21, 2025
- Beihai Kangcheng’s Velaglucerase β for Injection is Approved for Marketing in China May 21, 2025
- FDA filing is about to start, and one medical device has completed its first human clinical trial May 21, 2025
- Phase I clinical drugs can bypass the FDA and go directly to market May 21, 2025
- Pfizer has been granted authorization for the dual drug of Sansheng Guojian; Huashen Technology Received Administrative Supervision Measures Decision from Sichuan Securities Regulatory Bureau | Medical Early Reference May 21, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
